Fiona Thistlethwaite

Fiona Thistlethwaite

Auto-generated profile, based on publicly available information

Fiona Thistlethwaite

Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1998 in Molecular Cell
Verified
Journal Article
Closed access
KPKetan J Patel
Ketan J Patel
VYVeronica P.C.C Yu
Veronica P.C.C Yu
HLHyunsook Lee
Hyunsook Lee
ACAnne Corcoran
Anne Corcoran
FTFiona C Thistlethwaite
Fiona C Thistlethwaite
AVAshok R Venkitaraman
Ashok R Venkitaraman

28 June 2017 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
FTFiona C. Thistlethwaite
Fiona C. Thistlethwaite
DGDavid E. Gilham
David E. Gilham
RGRyan D. Guest
Ryan D. Guest
DRDominic Rothwell
Dominic Rothwell
MPManon Pillai
Manon Pillai
RHRobert E. Hawkins
Robert E. Hawkins
The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5+ malignancy. Secondary aims were to assess clinical efficacy, immune effector function and optimal dose of CAR T cells. Three cohorts of patients received increasing doses of CEACAM5+-specific CAR T cells after fludarabine pre-conditioning plus systemic IL2 support post T cell infusion. Patients in cohort 4 received increased intensity pre-conditioning (cyclophosphamide and fludarabine), systemic IL2 support and CAR T cells. No objective clinical responses were observed. CAR T cell engraftment in patients within cohort 4 was significantly higher. However, engraftment was short-lived with a rapid decline of systemic CAR T cells within 14 days. Patients in cohort 4 had transient, acute respiratory toxicity which, in combination with lack of prolonged CAR T cell persistence, resulted in the premature closure of the trial. Elevated levels of systemic IFNγ and IL-6 implied that the CEACAM5-specific T cells had undergone immune activation in vivo but only in patients receiving high-intensity pre-conditioning. Expression of CEACAM5 on lung epithelium may have resulted in this transient toxicity. Raised levels of serum cytokines including IL-6 in these patients implicate cytokine release as one of several potential factors exacerbating the observed respiratory toxicity. Whilst improved CAR designs and T cell production methods could improve the systemic persistence and activity, methods to control CAR T ‘on-target, off-tissue’ toxicity are required to enable a clinical impact of this approach in solid malignancies.

28 February 2010 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CRChristy Ralph
Christy Ralph
Eyad ElkordEyad Elkord
Eyad Elkord
DBDeborah J. Burt
Deborah J. Burt
JOJackie F. O'DWyer
Jackie F. O'DWyer
EAEric B. Austin
Eric B. Austin
FTFiona C. Thistlethwaite
Fiona C. Thistlethwaite
Purpose: Cytotoxic T lymphocyte antigen 4 (CTLA4), a key negative regulator of T-cell activation, is targeted by the antibody tremelimumab to release potentially useful antitumor activity. Experimental Design: This phase II trial investigated tremelimumab as a second-line treatment for patients with metastatic gastric and esophageal adenocarcinomas. Tremelimumab was given every 3 months until symptomatic disease progression. Safety, clinical efficacy, and immunologic activity were evaluated. Results: Eighteen patients received tremelimumab. Most drug-related toxicity was mild; however, there was a single death due to bowel perforation that complicated colitis. Four patients had stable disease with clinical benefit; one patient achieved a partial response after eight cycles (25.4 months) and remains well on study at 32.7 months. Markers of regulatory phenotype, forkhead box protein 3 and CTLA4, doubled transiently in CD4+CD25high lymphocytes in the first month after tremelimumab before returning to baseline. In contrast, CTLA4 increased in CD4+CD25low/negative lymphocytes throughout the cycle of treatment. De novo proliferative responses to tumor-associated antigens 5T4 (8 of 18 patients) and carcinoembryonic antigen (5 of 13) were detected. Patients with a posttreatment carcinoembryonic antigen proliferative response had median survival of 17.1 months compared with 4.7 months for nonresponders (P = 0.004). Baseline interleukin-2 release after T-cell activation was higher in patients with clinical benefit and toxicity. Conclusion: Despite the disappointing response rate of tremelimumab, one patient had a remarkably durable benefit for this poor-prognosis disease. In vitro evidence of enhanced proliferative responses to relevant tumor-associated antigens suggests that combining CTLA4 blockade with antigen-targeted therapy may warrant further investigation. Clin Cancer Res; 16(5); 1662–72

1 July 1999 in Molecular Cell
Verified
Journal Article
Closed access
HLHyunsook Lee
Hyunsook Lee
ATAlison H Trainer
Alison H Trainer
LFLori S Friedman
Lori S Friedman
FTFiona C Thistlethwaite
Fiona C Thistlethwaite
MEMartin J Evans
Martin J Evans
AVAshok R Venkitaraman
Ashok R Venkitaraman

1 January 2011 in Clinical Immunology
Verified
Journal Article
Closed access
SKSameena Khan
Sameena Khan
DBDeborah J. Burt
Deborah J. Burt
CRChristy Ralph
Christy Ralph
FTFiona C. Thistlethwaite
Fiona C. Thistlethwaite
RHRobert E. Hawkins
Robert E. Hawkins
Eyad ElkordEyad Elkord
Eyad Elkord

1 April 1998
Verified
Journal Article
Closed access
LFL S Friedman
L S Friedman
FTF C Thistlethwaite
F C Thistlethwaite
KPK J Patel
K J Patel
VYV P Yu
V P Yu
HLH Lee
H Lee
BPB A Ponder
B A Ponder